Shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) rose 3.3% on Tuesday . The company traded as high as $21.20 and last traded at $21.30. Approximately 2,162 shares traded hands during trading, a decline of 51% from the average daily volume of 4,400 shares. The stock had previously closed at $20.61.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on VTVT. HC Wainwright reissued a "buy" rating and set a $36.00 price objective on shares of vTv Therapeutics in a report on Wednesday, August 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of vTv Therapeutics in a report on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $35.50.
Read Our Latest Research Report on vTv Therapeutics
vTv Therapeutics Price Performance
The firm has a market cap of $83.92 million, a PE ratio of -6.83 and a beta of 0.67. The company has a 50 day simple moving average of $19.75 and a 200-day simple moving average of $18.23.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.07).
Institutional Trading of vTv Therapeutics
An institutional investor recently bought a new position in vTv Therapeutics stock. Connective Capital Management LLC acquired a new stake in vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 9,377 shares of the biotechnology company's stock, valued at approximately $162,000. Connective Capital Management LLC owned 0.29% of vTv Therapeutics at the end of the most recent quarter. Institutional investors own 17.51% of the company's stock.
About vTv Therapeutics
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
